


Ac-YVAD-CHO acetate

Cat. No.:	HY-120019A
Molecular Formula:	C ₂₅ H ₃₆ N ₄ O ₁₀
Molecular Weight:	552.57
Target:	Interleukin Related; Caspase; Apoptosis
Pathway:	Immunology/Inflammation; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ac-YVAD-CHO (L-709049) acetate is a potent, reversible, specific tetrapeptide interleukin-1 β converting enzyme (ICE) inhibitor with mouse and human K _i values of 3.0 and 0.76 nM. Ac-YVAD-CHO acetate is also a caspase-1 inhibitor. Ac-YVAD-CHO acetate can suppress the production of mature IL-1 β [1][2][3].									
IC₅₀ & Target	Caspase-1	IL-1 β								
In Vitro	<p>Ac-YVAD-CHO acetate inhibits mouse and human IL-1β with IC₅₀ values of 2.5 and 0.7 μM respectively^[1]. Ac-YVAD-CHO (0.01-100 μM) acetate reduces the elevations of IL-1β in the plasma and peritoneal fluid treated with LPS^[1]. Ac-YVAD-CHO (15.6 μM) acetate reduces NO-induced thymocyte apoptosis^[3]. Ac-YVAD-CHO (15.6 μM, 12 h) acetate inhibits NO-induced PARP cleavage in SNAP-treated thymocytes^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[3]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SNAP-treated thymocytes</td> </tr> <tr> <td>Concentration:</td> <td>15.6 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>12 h</td> </tr> <tr> <td>Result:</td> <td>Reduced PARP cleavage.</td> </tr> </table>		Cell Line:	SNAP-treated thymocytes	Concentration:	15.6 μ M	Incubation Time:	12 h	Result:	Reduced PARP cleavage.
Cell Line:	SNAP-treated thymocytes									
Concentration:	15.6 μ M									
Incubation Time:	12 h									
Result:	Reduced PARP cleavage.									
In Vivo	<p>Ac-YVAD-CHO (30 mg/kg; i.p.; 6 hours) acetate suppresses IL-1β levels in blood of P. acnes-sensitized mice^[1]. Ac-YVAD-CHO (2-8 μg, intrastriatal infusion) acetate attenuates Quinolinic acid (QA)-induced apoptosis in rat striatum^[2]. Ac-YVAD-CHO (10 and 50 mg/kg; i.p.; 1 hour) acetate is cleared from the blood rapidly, and drops precipitously to approximately 1 and 0.2 μM at 30 and 60 minutes after injection^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>P. acnes-sensitized mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.</td> </tr> </table>		Animal Model:	P. acnes-sensitized mice ^[1]	Dosage:	50 mg/kg	Administration:	i.p.		
Animal Model:	P. acnes-sensitized mice ^[1]									
Dosage:	50 mg/kg									
Administration:	i.p.									

Result:	Suppressed IL-1 β levels in blood.
Animal Model:	Quinolinic acid-treated Rats ^[2]
Dosage:	2-8 μ g
Administration:	Intrastriatal infusion.
Result:	Attenuated Quinolinic acid (QA)-induced increases in p53 and apoptosis in rat striatum. Inhibited QA-induced increases in caspase-1 activity and p53 protein levels, with no effect on QA-induced I κ B- α degradation, NF- κ B or AP-1 activation.

REFERENCES

- [1]. Fletcher DS, et al. A synthetic inhibitor of interleukin-1 beta converting enzyme prevents endotoxin-induced interleukin-1 beta production in vitro and in vivo. *J Interferon Cytokine Res.* 1995;15(3):243-248.
- [2]. Cao Y, et al. Caspase-1 inhibitor Ac-YVAD-CHO attenuates quinolinic acid-induced increases in p53 and apoptosis in rat striatum. *Acta Pharmacol Sin.* 2005 Feb;26(2):150-4.
- [3]. Zhou X, et al. Nitric oxide induces thymocyte apoptosis via a caspase-1-dependent mechanism. *J Immunol.* 2000 Aug 1;165(3):1252-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA